|
|||
2009-07-23 12:15:00 CEST 2009-07-23 12:17:04 CEST REGULATED INFORMATION Biotie Therapies - Major shareholder announcementsNotification according to Chapter 2, Section 10 of the Finnish Securities Market ActBIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE July 23, 2009, at 1:15 p.m. Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act Biotie Therapies Corp. ("the Company" or "Biotie") has on July 22, 2009 gained knowledge of the notifications regarding the following changes in holdings in accordance with Chapter 2, Section 9 of the Finnish Securities Markets Act. Elbion NV, Biotie's current largest shareholder, has notified the Company that as a result of a series of share transactions carried out on July 20, 2009, the holdings of elbion NV in the Company have decreased from above 31.20% to below 5%. As a consequence, elbion NV has no longer the obligation to make a public tender offer in accordance with Chapter 6, Section 10 of the Finnish Securities Markets Act. In November 2008, elbion NV was granted an exemption from the obligation to make such a public tender offer for all the Biotie shares even though its holdings exceeded 3/10 of the voting rights attached to all shares of the Company. The originally granted exemption provided for a reduction of the elbion NV voting rights in Biotie referred to in Chapter 6, Section 10 of the Finnish Securities Markets Act to or below 3/10 within nine months from the date the Shares issued to elbion NV in connection with the Exchange Offer had been entered into the Trade Register. Moreover, TVM Life Science Ventures VI GmbH & Co. KG and Burrill & Company LLC have notified the Company that as a result of these share transactions carried out on July 20, 2009, the aggregate holdings of these shareholders have increased to above 10% and 5% respectively. The changes in holdings in accordance with Chapter 2, Section 9 of the Finnish Securities Markets Act of which the Company has gained knowledge are described below. Name of the shareholder Shares % of shares after the after the transactions transactions elbion NV 1,351,613 0.9 TVM Life Science Ventures VI GmbH 15,302,500 10.6& Co. KG (HRA 84941) Funds managed by Burrill & Company 10,412,744 7.2 LLC. The registered number of shares in Biotie Therapies Corp. is 144,320,560 and the number of voting rights attached to the shares amounts to 144,320,560. Turku, July 23, 2009 Timo Veromaa President and CEO For further information, please contact: Virve Nurmi, Investor Relations Manager Biotie Therapies Corp. tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com DISTRIBUTION NASDAQ OMX Helsinki Ltd Main Media |
|||
|